Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 28

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 28
---
 exclusively license the certain patent and technology rights held by FSURF relating
to methods for purifying castanospermine and its use for the treatment of COVID-19.

On August 19, 2021, we entered into an Option
Agreement with FSURF, subsequently amended on February 15, 2023, that granted an option, effective through August 19, 2024, to us to license
certain patent and technology rights held by FSURF relating to the use of alpha glucosidase inhibitors (including castanospermine and
Celgosivir) for treatment of Zika infections. Upon expiration of the previous Option Agreement, we entered into a subsequent Option Agreement
on March 24, 2025, with FSURF pursuant to which FSURF granted us a 12-month option to exclusively license the certain patent and technology
rights held by FSURF relating to the use of alpha glucosidase inhibitors (including castanospermine and Celgosivir) for treatment of Zika
infections.

On April 4, 2025, we entered into an Option Agreement
with FSURF, pursuant to which FSURF granted us a 12-month option to exclusively license certain patent and technology rights held by FSURF
relating to large scale purification of castanospermine, including U.S. Patent No. 11,518,762, while we assess the potential feasibility
of commercializing Australian chestnut tree extracts.

Ending upon July 12, 2033 or the conversion or
redemption in full of all of the shares of Series A Preferred Stock owned by Knight, we will pay Knight a royalty equal to 3.5% of our
net sales, where “net sales” has the same meaning as in our license agreement with the U.S. Army for Tafenoquine. At the end
of the quarter and each thereafter the royalty will be calculated, and payment will be made within fifteen days.

On April 3, 2025, we entered into an Agreement
with Yale University (“Yale”) pursuant to which Yale has granted us an exclusive, worldwide license to make, have made, use,
sell, have sold, import, or practice certain patents and patent applications covering jointly developed inventions related to the treatment
of babesiosis using Tafenoquine within the field of using Tafenoquine to treat babesiosis. Yale retains the right to make, use, and practice
the licensed patents and